BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, Tomlinson AD, Nandakumar M, Cook DN, Pomerantz RJ, Auninš JG, Trucksis M. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis 2021;72:2132-40. [PMID: 32255488 DOI: 10.1093/cid/ciaa387] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Szychowiak P, Villageois-Tran K, Patrier J, Timsit JF, Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care 2022;12:3. [PMID: 34985651 DOI: 10.1186/s13613-021-00976-5] [Reference Citation Analysis]
2 Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson AD, Cook DN, Pomerantz RJ, Misra BK, Auninš JG, Trucksis M. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis. Gastroenterology 2021;160:115-127.e30. [PMID: 32763240 DOI: 10.1053/j.gastro.2020.07.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Staley C, Halaweish H, Graiziger C, Hamilton MJ, Kabage AJ, Galdys AL, Vaughn BP, Vantanasiri K, Suryanarayanan R, Sadowsky MJ, Khoruts A. Lower endoscopic delivery of freeze-dried intestinal microbiota results in more rapid and efficient engraftment than oral administration. Sci Rep 2021;11:4519. [PMID: 33633264 DOI: 10.1038/s41598-021-84152-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Khanna S. Fecal transplant clinical trials for Clostridioides difficile: an interview with Sahil Khanna. Future Microbiol 2020;15:709-12. [PMID: 32677453 DOI: 10.2217/fmb-2020-0102] [Reference Citation Analysis]
5 Poylin V, Hawkins AT, Bhama AR, Boutros M, Lightner AL, Khanna S, Paquette IM, Feingold DL; Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum 2021;64:650-68. [PMID: 33769319 DOI: 10.1097/DCR.0000000000002047] [Reference Citation Analysis]
6 Buckley AM, Moura IB, Wilcox MH. The potential of microbiome replacement therapies for Clostridium difficile infection. Curr Opin Gastroenterol 2022;38:1-6. [PMID: 34871192 DOI: 10.1097/MOG.0000000000000800] [Reference Citation Analysis]
7 Segal JP, Mullish BH, Quraishi MN, Iqbal T, Marchesi JR, Sokol H. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therap Adv Gastroenterol 2020;13:1756284820946904. [PMID: 32952613 DOI: 10.1177/1756284820946904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Wensel CR, Pluznick JL, Salzberg SL, Sears CL. Next-generation sequencing: insights to advance clinical investigations of the microbiome. J Clin Invest 2022;132:e154944. [PMID: 35362479 DOI: 10.1172/JCI154944] [Reference Citation Analysis]
9 Tortajada-Girbés M, Rivas A, Hernández M, González A, Ferrús MA, Pina-Pérez MC. Alimentary and Pharmaceutical Approach to Natural Antimicrobials against Clostridioides difficile Gastrointestinal Infection. Foods 2021;10:1124. [PMID: 34069413 DOI: 10.3390/foods10051124] [Reference Citation Analysis]
10 Saha S, Pardi DS, Khanna S. Reply. Gastroenterology 2021:S0016-5085(21)03162-0. [PMID: 34174246 DOI: 10.1053/j.gastro.2021.06.048] [Reference Citation Analysis]
11 Halaweish HF, Boatman S, Staley C. Encapsulated Fecal Microbiota Transplantation: Development, Efficacy, and Clinical Application. Front Cell Infect Microbiol 2022;12:826114. [DOI: 10.3389/fcimb.2022.826114] [Reference Citation Analysis]
12 Qiu K, Huang Y, Anselmo AC. Polymer and Crosslinker Content Influences Performance of Encapsulated Live Biotherapeutic Products. Cell Mol Bioeng 2021;14:487-99. [PMID: 34777606 DOI: 10.1007/s12195-021-00674-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cruz N, Abernathy GA, Dichosa AEK, Kumar A. The Age of Next-Generation Therapeutic-Microbe Discovery: Exploiting Microbe-Microbe and Host-Microbe Interactions for Disease Prevention. Infect Immun 2022;:e0058921. [PMID: 35384688 DOI: 10.1128/iai.00589-21] [Reference Citation Analysis]
14 Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211017725. [PMID: 34104212 DOI: 10.1177/17562848211017725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Reference Citation Analysis]
16 Giovanni MY, Schneider JS, Calder T, Fauci AS. Refocusing Human Microbiota Research in Infectious and Immune-mediated Diseases: Advancing to the Next Stage. J Infect Dis 2021;224:5-8. [PMID: 33188418 DOI: 10.1093/infdis/jiaa706] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Kazemian N, Kao D, Pakpour S. Fecal Microbiota Transplantation during and Post-COVID-19 Pandemic. Int J Mol Sci 2021;22:3004. [PMID: 33809421 DOI: 10.3390/ijms22063004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med 2021;290:294-309. [PMID: 33856727 DOI: 10.1111/joim.13290] [Reference Citation Analysis]
19 Isles NS, Mu A, Kwong JC, Howden BP, Stinear TP. Gut microbiome signatures and host colonization with multidrug-resistant bacteria. Trends in Microbiology 2022. [DOI: 10.1016/j.tim.2022.01.013] [Reference Citation Analysis]
20 Ting NL, Lau HC, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut. [DOI: 10.1136/gutjnl-2021-326264] [Reference Citation Analysis]
21 Mehta SR, Yen EF. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Transl Res 2021;230:197-207. [PMID: 33278650 DOI: 10.1016/j.trsl.2020.11.013] [Reference Citation Analysis]
22 Fishbein SR, Robinson JI, Hink T, Reske KA, Newcomer EP, Burnham CD, Henderson JP, Dubberke ER, Dantas G. Multi-omics investigation of Clostridioides difficile-colonized patients reveals pathogen and commensal correlates of C. difficile pathogenesis. Elife 2022;11:e72801. [PMID: 35083969 DOI: 10.7554/eLife.72801] [Reference Citation Analysis]
23 Qian Y, Lan F, Venturelli OS. Towards a deeper understanding of microbial communities: integrating experimental data with dynamic models. Curr Opin Microbiol 2021;62:84-92. [PMID: 34098512 DOI: 10.1016/j.mib.2021.05.003] [Reference Citation Analysis]
24 Zhang Y, Saint Fleur A, Feng H. The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota. Gut Microbes 2022;14:2052698. [PMID: 35319337 DOI: 10.1080/19490976.2022.2052698] [Reference Citation Analysis]
25 Fukaya-Shiba A, Otsuka K, Sasaki H, Shikano M, Wakao R. Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity. Front Med (Lausanne) 2021;8:756870. [PMID: 34708061 DOI: 10.3389/fmed.2021.756870] [Reference Citation Analysis]
26 Young VB. Unexpected Results From a Phase 2 Trial of a Microbiome Therapeutic for Clostridioides difficile Infection: Lessons for the Future. Clin Infect Dis 2021;72:2141-3. [PMID: 32330238 DOI: 10.1093/cid/ciaa476] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdecha S, Janvilisri T. Frontiers in antibiotic alternatives for Clostridioides difficile infection. World J Gastroenterol 2021; 27(42): 7210-7232 [PMID: 34876784 DOI: 10.3748/wjg.v27.i42.7210] [Reference Citation Analysis]
28 Kao D, Wong K, Franz R, Cochrane K, Sherriff K, Chui L, Lloyd C, Roach B, Bai AD, Petrof EO, Allen-Vercoe E. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol Hepatol 2021;6:282-91. [PMID: 33631102 DOI: 10.1016/S2468-1253(21)00007-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections. Clin Infect Dis 2021;73:e1613-20. [PMID: 32966574 DOI: 10.1093/cid/ciaa1430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
30 Qiu K, Anselmo AC. Batch Culture Formulation of Live Biotherapeutic Products. Adv Ther (Weinh) 2021;4:2000226. [PMID: 33709021 DOI: 10.1002/adtp.202000226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Qiu K, Anselmo AC. Enhanced Storage of Anaerobic Bacteria through Polymeric Encapsulation. ACS Appl Mater Interfaces 2021;13:46282-90. [PMID: 34558893 DOI: 10.1021/acsami.1c11785] [Reference Citation Analysis]
32 Strati F, Lattanzi G, Amoroso C, Facciotti F. Microbiota-targeted therapies in inflammation resolution. Semin Immunol 2022;:101599. [PMID: 35304068 DOI: 10.1016/j.smim.2022.101599] [Reference Citation Analysis]
33 Sung JJY, Wong SH. What is unknown in using microbiota as a therapeutic? J Gastroenterol Hepatol 2021. [PMID: 34668228 DOI: 10.1111/jgh.15716] [Reference Citation Analysis]
34 Du C, Luo Y, Walsh S, Grinspan A. Oral Fecal Microbiota Transplant Capsules Are Safe and Effective for Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2021;55:300-8. [PMID: 33471490 DOI: 10.1097/MCG.0000000000001495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
35 Wilcox MH, McGovern BH, Hecht GA. The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis. Open Forum Infect Dis 2020;7:ofaa114. [PMID: 32405509 DOI: 10.1093/ofid/ofaa114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
36 Hryckowian AJ. Microbiome Management for the 21st Century and Beyond. mSystems 2021;:e0076021. [PMID: 34463571 DOI: 10.1128/mSystems.00760-21] [Reference Citation Analysis]